Clinical trials: Moderate-to-severe Chronic Plaque Psoriasis
Chronic Plaque Psoriasis
Chronic Plaque Psoriasis (Ps) Registry
The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).
- Trial name
- NCT00799877
- Where
- 339 sites in United States, Austria and 12 more
- Volunteers
- 6,065 people
- Sponsor
- AbbVie
Chronic Plaque Psoriasis
TRUST Study: Raptiva ® in Hand & Foot Psoriasis
To evaluate the safety and efficacy of Raptiva ® compared with placebo to control chronic moderate to severe plaque psoriasis involving the hands and/or feet scoring Physician's Global Assessment (PGA - H\&F) greater-than or…
- Trial name
- TRUST (NCT00739882)
- Testing
- Efalizumab - anti CD11a recombinant human monoclonal antibody
- Where
- Austria
- Volunteers
- 76 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psoriasis
ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.
- Trial name
- NCT01208090
- Testing
- ACT-128800
- Where
- 67 sites in Austria, Belgium and 15 more
- Volunteers
- 326 people
- Sponsor
- Actelion
Plaque Type Psorisis
A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)
A study to evaluate the differences in the efficacy and safety of secukinumab between Cw6-negative and Cw6-positive patients with moderate to severe plaque-type psoriasis
- Trial name
- SUPREME (NCT02394561)
- Testing
- Secukinumab
- Where
- 45 sites in Italy
- Volunteers
- 434 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Plaque-type Psoriasis
Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
This was an extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab.
- Trial name
- NCT01544595
- Testing
- Secukinumab (AIN457)
- Where
- 182 sites in United States, Argentina and 24 more
- Volunteers
- 1,147 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis
The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 [NCT00245765] and Week 12 of re-treatment in this study.
- Trial name
- NCT00329303
- Testing
- Certolizumab Pegol (Cimzia®)
- Where
- 14 sites in France, Germany
- Volunteers
- 71 people
- Sponsor
- UCB Pharma
Psoriasis
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
To evaluate the efficacy and to compare efficacy and safety of BI 695501 versus Humira in patients with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT02850965
- Testing
- BI 695501, Humira
- Where
- 54 sites in United States, Czechia and 6 more
- Volunteers
- 318 people
- Sponsor
- Boehringer Ingelheim
Psoriasis Chronic
Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs
The aim of this post-marketing observational study (PMOS) was to obtain further data on long-term safety, efficacy, and quality of life outcomes for adalimumab in routine clinical use in participants with moderate to severe…
- Trial name
- QUALITY (NCT01084668)
- Where
- 9 sites in Austria
- Volunteers
- 46 people
- Sponsor
- Abbott
Moderate to Severe Psoriasis
Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis
This is a single-center, open-label, pilot study. A total of 18 subjects will be enrolled in this 6 month study to evaluate whether the response to intralesional alefacept injections prior to the standard course of…
- Trial name
- NCT00678470
- Testing
- Intralesional Alefacept
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Psoriasis
A Study to Evaluate the Efficacy and Safety of LZM012
This study is a muti-center, randomized, double blind, positive control phase III clinical study to evaluate the efficacy and safety of LZM012 in moderate to severe chronic plaque psoriasis patients
- Trial name
- Psoriasis (NCT06110676)
- Testing
- LZM012, Secukinumab
- Where
- China
- Volunteers
- 918 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Chronic Plaque Type Psoriasis
Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis
- Trial name
- NCT02074982
- Testing
- AIN457 300 mg, ustekinumab 45/90 mg
- Where
- 137 sites in United States, Australia and 22 more
- Volunteers
- 676 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque-type Psoriasis
A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis
This will be a multicenter, double-blind, double-dummy, placebo controlled, randomized study to evaluate efficacy and safety of AUR101 (RORgamma inhibitor) in patients with moderate-to-severe psoriasis.
- Trial name
- INDUS-2 (NCT04207801)
- Testing
- AUR101
- Where
- 9 sites in India
- Volunteers
- 90 people
- Sponsor
- Aurigene Discovery Technologies Limited
Psoriasis
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support…
- Trial name
- NCT02694523
- Testing
- risankizumab, adalimumab
- Volunteers
- 684 people
- Sponsor
- AbbVie
Chronic Plaque-type Psoriasis
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body…
- Trial name
- NCT00941031
- Testing
- AIN457, AIN457A
- Where
- 62 sites in United States, France and 5 more
- Volunteers
- 404 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis.
- Trial name
- CIMPASI-2 (NCT02326272)
- Testing
- Certolizumab Pegol
- Where
- 23 sites in United States, Austria and 2 more
- Volunteers
- 227 people
- Sponsor
- UCB Biopharma S.P.R.L.
Moderate to Severe Chronic Plaque Psoriasis
A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China
This was a non-interventional, prospective, multi-center real world setting study, aiming to provide safety and effectiveness data in Chinese pediatric patients with moderate to severe plaque psoriasis treated with Cosentyx® for…
- Trial name
- NCT05388916
- Testing
- Cosentyx
- Where
- 7 sites in China
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Moderate-to-severe Chronic Plaque Psoriasis
Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis
This is a multi-regional, randomized, double-blind, placebo-controlled, clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SHR-1314 in adults with moderate-to-severe plaque psoriasis.
- Trial name
- NCT03463187
- Testing
- SHR-1314
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 211 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Plaque Psoriasis
Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis
Pharmacokinetic, Efficacy, Safety, and Immunogenicity Between Patients with Moderate to Severe Chronic Plaque Psoriasis Receiving Humira® and Patients with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT04453137
- Testing
- Adalimumab originator, Adalimumab biosimilar
- Where
- 25 sites in Georgia, Iceland and 3 more
- Volunteers
- 567 people
- Sponsor
- Alvotech Swiss AG
Plaque Psoriasis
TSO for Plaque Psoriasis
This is a randomized, blinded, multicenter study to assess the safety and treatment effect of 12 weeks of Trichuris suis ova in subjects diagnosed with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT02011269
- Testing
- Trichuris Suis Ova
- Sponsor
- Coronado Biosciences, Inc.
Plaque Psoriasis
A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to determine the safety and efficacy of 2 doses of ABT-874 versus placebo in the treatment of subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT00570986
- Testing
- ABT-874
- Where
- 116 sites in United States, Canada
- Volunteers
- 1,465 people
- Sponsor
- AbbVie (prior sponsor, Abbott)